PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Clinical trials for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE explained in plain language.
Never miss a new study
Get alerted when new PULMONARY DISEASE, CHRONIC OBSTRUCTIVE trials appear
Sign up with your email to follow new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New shot aims to tame dangerous COPD Flare-Ups
Disease control Recruiting nowThis study is testing if adding a new injectable medicine called depemokimab to standard inhaler treatments can help people with moderate-to-severe COPD. The main goal is to see if it reduces the number of serious breathing flare-ups that require steroids, antibiotics, or hospita…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Can your local pharmacist manage your lung disease as well as a specialist? major VA trial aims to find out
Disease control Recruiting nowThis study tests whether clinical pharmacists can manage chronic obstructive pulmonary disease (COPD) as effectively as lung specialists. It involves 4000 patients across five Veterans Affairs medical centers. The goal is to see if a team-based approach using electronic recommend…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: NA • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New shot aims to tame dangerous COPD Flare-Ups
Disease control Recruiting nowThis study is testing whether a new injectable medicine called depemokimab can help control chronic obstructive pulmonary disease (COPD) in adults who still have frequent symptom flare-ups despite using standard inhalers. The main goal is to see if the medicine can reduce the num…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New inhaler aims to help COPD patients breathe easier
Disease control Recruiting nowThis study is testing an investigational inhaled powder called TQC3721 for people with moderate to severe COPD. The main goal is to see if it safely improves lung function and reduces symptoms compared to a placebo. About 195 participants will use the inhaler for four weeks while…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Common aspirin could ease breathing for millions with COPD
Disease control Recruiting nowThis study is testing which daily dose of aspirin (81mg, 162mg, or 325mg) best reduces blood cell inflammation linked to worse COPD symptoms. Researchers will enroll 48 adults with COPD who are former smokers. The goal is to find the most effective dose to inform a larger future …
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Tracking a year of COPD care: does a triple therapy deliver?
Disease control Recruiting nowThis study looks back at data from real-world patients with moderate to severe COPD who started a triple-combination inhaler (BGF). It aims to see how their symptoms, quality of life, and number of flare-ups change over 12 months compared to before starting the treatment. The goa…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC